PE20050352A1 - Derivados de 7-indolilsulfonamidas y su preparacion como medicamentos - Google Patents
Derivados de 7-indolilsulfonamidas y su preparacion como medicamentosInfo
- Publication number
- PE20050352A1 PE20050352A1 PE2004000738A PE2004000738A PE20050352A1 PE 20050352 A1 PE20050352 A1 PE 20050352A1 PE 2004000738 A PE2004000738 A PE 2004000738A PE 2004000738 A PE2004000738 A PE 2004000738A PE 20050352 A1 PE20050352 A1 PE 20050352A1
- Authority
- PE
- Peru
- Prior art keywords
- radical
- indol
- pyrrolidin
- sulfonamide
- ethyl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 150000003254 radicals Chemical class 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 3
- 108091005435 5-HT6 receptors Proteins 0.000 abstract 1
- 208000032841 Bulimia Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- 150000003456 sulfonamides Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
REFERIDA A COMPUESTOS DERIVADOS DE SULFONAMIDA, DE FORMULA Ia, EN LA QUE R1 ES UN RADICAL CICLOALIFATICO SATURADO O INSATURADO, O UN RADICAL -NR8R9; R2, R3, R4, R5 Y R6 SON CADA UNO H, HALOGENO, NITRO, ENTRE OTROS; R7 ES H, RADICAL ALIFATICO LINEAL O RAMIFICADO; R8 Y R9 SON CADA UNO H O RADICAL ALIFATICO LINEAL O RAMIFICADO; n ES 0-4. TAMBIEN REFERIDO A UN PROCEDIMIENTO PARA LA PREPARACION DE ESTOS COMPUESTOS CUYOS PREFERIDOS SON: 5-CLORO-3-METIL-N-{1[2-(PIRROLIDIN-1-IL)ETIL]-1H-INDOL-7-IL}BENZO[b]TIOFENO-2-SULFONAMIDA, N-{1-[2-(PIRROLIDIN-1-IL)ETIL]-1H-INDOL-7-IL}IMIDAZO[2,1-b]TIAZOL-5-SULFONAMIDA Y 2-(NAFTALEN-1-IL)-N-{1-[2-(PIRROLIDIN-1-IL)ETIL]-1H-INDOL-7-IL}ETANOSULFONAMIDA, ENTRE OTROS. DICHOS COMPUESTOS INTERVIENEN EN LA REGULACION DEL RECEPTOR 5-HT6 Y SON UTILES PARA EL TRATAMIENTO DE LA OBESIDAD, BULIMIA, CAQUEXIA, ENTRE OTRAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200301808A ES2222830B1 (es) | 2003-07-30 | 2003-07-30 | Derivados de 7-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20050352A1 true PE20050352A1 (es) | 2005-06-12 |
Family
ID=34130542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2004000738A PE20050352A1 (es) | 2003-07-30 | 2004-08-02 | Derivados de 7-indolilsulfonamidas y su preparacion como medicamentos |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7414070B2 (es) |
| EP (1) | EP1648444B1 (es) |
| JP (1) | JP2007500167A (es) |
| KR (1) | KR20060036457A (es) |
| CN (1) | CN1832739A (es) |
| AR (1) | AR045158A1 (es) |
| AT (1) | ATE432698T1 (es) |
| AU (1) | AU2004262487A1 (es) |
| BR (1) | BRPI0413001A (es) |
| CA (1) | CA2534136A1 (es) |
| DE (1) | DE602004021383D1 (es) |
| EC (1) | ECSP066323A (es) |
| ES (2) | ES2222830B1 (es) |
| IL (1) | IL172750A0 (es) |
| MX (1) | MXPA06001130A (es) |
| NO (1) | NO20060506L (es) |
| NZ (1) | NZ545298A (es) |
| PE (1) | PE20050352A1 (es) |
| PT (1) | PT1648444E (es) |
| RU (1) | RU2006105791A (es) |
| TW (1) | TW200510433A (es) |
| WO (1) | WO2005013979A1 (es) |
| ZA (1) | ZA200600418B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2018861A1 (en) * | 2007-07-26 | 2009-01-28 | Laboratorios del Dr. Esteve S.A. | 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain |
| EP2020230B1 (en) | 2007-08-01 | 2011-01-19 | Laboratorios del Dr. Esteve S.A. | Combination of at least two 5-HT6-Ligands |
| EP2053052A1 (en) | 2007-10-23 | 2009-04-29 | Laboratorios del Dr. Esteve S.A. | Process for the preparation of 6-substituted imidazo[2,1-b]thiazole-5-sulfonyl halide |
| US20190336585A1 (en) * | 2018-05-03 | 2019-11-07 | John Lawrence Mee | Method for sustainable human cognitive enhancement |
| US20190390193A1 (en) * | 2018-06-23 | 2019-12-26 | John Lawrence Mee | Reversible method for sustainable human cognitive enhancement |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3472870A (en) | 1966-08-29 | 1969-10-14 | Mead Johnson & Co | Sulfonamidotryptamines |
| US5939451A (en) | 1996-06-28 | 1999-08-17 | Hoffmann-La Roche Inc. | Use of sulfonamides |
| TWI242011B (en) | 1997-03-31 | 2005-10-21 | Eisai Co Ltd | 1,4-substituted cyclic amine derivatives |
| DE19753522A1 (de) * | 1997-12-03 | 1999-06-10 | Boehringer Ingelheim Pharma | Substituierte Indole, ihre Herstellung und ihre Verwendung als Arzneimittel |
| JP2002167376A (ja) * | 2000-11-30 | 2002-06-11 | Mercian Corp | 血管内皮細胞増殖因子発現抑制作用を有するインドール誘導体及びその用途 |
| WO2002060871A2 (en) | 2001-01-30 | 2002-08-08 | Eli Lilly And Company | Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor |
| US6488243B2 (en) * | 2001-04-06 | 2002-12-03 | Seong Tae Kim | Bag holder for hanging on rims of miscellaneous items |
| ES2187300B1 (es) | 2001-11-14 | 2004-06-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos. |
| EP1626715B1 (en) | 2003-05-09 | 2008-09-10 | Laboratorios Del Dr. Esteve, S.A. | Use of sulphonamide derivatives for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion |
-
2003
- 2003-07-30 ES ES200301808A patent/ES2222830B1/es not_active Expired - Fee Related
-
2004
- 2004-07-29 RU RU2006105791/04A patent/RU2006105791A/ru unknown
- 2004-07-29 ES ES04741320T patent/ES2327846T3/es active Active
- 2004-07-29 ZA ZA200600418A patent/ZA200600418B/en unknown
- 2004-07-29 TW TW093122674A patent/TW200510433A/zh unknown
- 2004-07-29 EP EP04741320A patent/EP1648444B1/en active Active
- 2004-07-29 AU AU2004262487A patent/AU2004262487A1/en not_active Abandoned
- 2004-07-29 DE DE602004021383T patent/DE602004021383D1/de active Active
- 2004-07-29 WO PCT/EP2004/008513 patent/WO2005013979A1/en active Application Filing
- 2004-07-29 JP JP2006521531A patent/JP2007500167A/ja active Pending
- 2004-07-29 CA CA002534136A patent/CA2534136A1/en not_active Abandoned
- 2004-07-29 KR KR1020067001022A patent/KR20060036457A/ko not_active Application Discontinuation
- 2004-07-29 BR BRPI0413001-4A patent/BRPI0413001A/pt not_active Application Discontinuation
- 2004-07-29 AR ARP040102700A patent/AR045158A1/es unknown
- 2004-07-29 CN CNA2004800223536A patent/CN1832739A/zh active Pending
- 2004-07-29 PT PT04741320T patent/PT1648444E/pt unknown
- 2004-07-29 MX MXPA06001130A patent/MXPA06001130A/es active IP Right Grant
- 2004-07-29 AT AT04741320T patent/ATE432698T1/de not_active IP Right Cessation
- 2004-07-29 NZ NZ545298A patent/NZ545298A/en unknown
- 2004-07-29 US US10/566,403 patent/US7414070B2/en not_active Expired - Fee Related
- 2004-08-02 PE PE2004000738A patent/PE20050352A1/es not_active Application Discontinuation
-
2005
- 2005-12-22 IL IL172750A patent/IL172750A0/en unknown
-
2006
- 2006-01-26 EC EC2006006323A patent/ECSP066323A/es unknown
- 2006-01-31 NO NO20060506A patent/NO20060506L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA06001130A (es) | 2006-04-24 |
| US7414070B2 (en) | 2008-08-19 |
| TW200510433A (en) | 2005-03-16 |
| ATE432698T1 (de) | 2009-06-15 |
| RU2006105791A (ru) | 2007-09-20 |
| CN1832739A (zh) | 2006-09-13 |
| EP1648444A1 (en) | 2006-04-26 |
| NZ545298A (en) | 2008-06-30 |
| ZA200600418B (en) | 2007-03-28 |
| CA2534136A1 (en) | 2005-02-17 |
| AR045158A1 (es) | 2005-10-19 |
| NO20060506L (no) | 2006-01-31 |
| KR20060036457A (ko) | 2006-04-28 |
| IL172750A0 (en) | 2006-04-10 |
| JP2007500167A (ja) | 2007-01-11 |
| EP1648444B1 (en) | 2009-06-03 |
| ES2222830B1 (es) | 2006-02-16 |
| BRPI0413001A (pt) | 2006-09-26 |
| WO2005013979A1 (en) | 2005-02-17 |
| PT1648444E (pt) | 2009-09-03 |
| ECSP066323A (es) | 2006-08-30 |
| ES2222830A1 (es) | 2005-02-01 |
| AU2004262487A1 (en) | 2005-02-17 |
| DE602004021383D1 (de) | 2009-07-16 |
| US20070185207A1 (en) | 2007-08-09 |
| ES2327846T3 (es) | 2009-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20050280A1 (es) | Derivados de 6-indolilsulfonamidas y su preparacion como medicamentos | |
| UY28150A1 (es) | Agentes terapeuticos | |
| AR054786A1 (es) | (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1 | |
| PE20061088A1 (es) | Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a | |
| ES2161231T3 (es) | Compuestos heterociclicos como antagonistas de bradiquinina. | |
| PE20010211A1 (es) | Compuestos de tiazol y composiciones farmaceuticas para inhibir las quinasas de proteina | |
| AR028824A1 (es) | Compuestos antagonistas npy-5 y su uso en la manufactura de medicamentos. | |
| ECSP034811A (es) | Derivados heterocicliloxi-, -tioxi - y - aminobenzazole tales como ligandos 5-hidroxitriptamina-6 | |
| PE20081689A1 (es) | Derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas y su preparacion | |
| AR024378A1 (es) | Gamma-carbolinas fusionadas heterociclicas sustituidas | |
| PE20080827A1 (es) | N-(1-hetaril-piperidin-4-il)-(het) arilamidas como moduladores del receptor ep2 | |
| ATE411323T1 (de) | Cgrp-rezeptorantagonisten | |
| ECSP055964A (es) | Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6 | |
| PE20060336A1 (es) | Compuestos derivados de 1-amino-ftalazina como moduladores de mch1 | |
| UY27976A1 (es) | Piperazinas heterocíclicas sustituídas para el tratamiento de la esquizofrenia | |
| PE20070115A1 (es) | Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas | |
| CO2021006482A2 (es) | Ureas cíclicas | |
| UY30287A1 (es) | Dihidrotienopirimidinas para el tratamiento de enfermedades inflamatorias | |
| PE20120881A1 (es) | Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) como moduladores del receptor de serotonina 5-ht6 | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| PE20081876A1 (es) | Aminoamidas como antagonistas de orexina | |
| CR7566A (es) | Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6 | |
| ECSP045156A (es) | Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6 | |
| CR10062A (es) | Composiciones y metodos de tratamiento para trastornos del sistema nervioso central | |
| PA8561501A1 (es) | Lactamas como antagonistas de taquiquininas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |